Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) EBITDA (2021 - 2025)

Amylyx Pharmaceuticals has reported EBITDA over the past 5 years, most recently at $86.3 million for Q4 2025.

  • Quarterly results put EBITDA at $86.3 million for Q4 2025, up 312.28% from a year ago — trailing twelve months through Dec 2025 was -$30.4 million (up 90.35% YoY), and the annual figure for FY2025 was -$30.4 million, up 90.35%.
  • EBITDA for Q4 2025 was $86.3 million at Amylyx Pharmaceuticals, up from -$36.0 million in the prior quarter.
  • Over the last five years, EBITDA for AMLX hit a ceiling of $86.3 million in Q4 2025 and a floor of -$122.1 million in Q1 2024.
  • Median EBITDA over the past 5 years was -$36.9 million (2025), compared with a mean of -$29.5 million.
  • Biggest five-year swings in EBITDA: plummeted 5848.86% in 2024 and later skyrocketed 312.28% in 2025.
  • Amylyx Pharmaceuticals' EBITDA stood at -$28.3 million in 2021, then plummeted by 57.49% to -$44.6 million in 2022, then soared by 104.34% to $1.9 million in 2023, then plummeted by 2202.07% to -$40.7 million in 2024, then skyrocketed by 312.28% to $86.3 million in 2025.
  • The last three reported values for EBITDA were $86.3 million (Q4 2025), -$36.0 million (Q3 2025), and -$42.9 million (Q2 2025) per Business Quant data.